Related Experiment Videos
Update on implantable cardioverter defibrillator trials
Abrar H Shah1, David T Huang, Spencer Z Rosero
1Department of Medicine, Box 679-Cardiology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Current Cardiology Reports
|August 13, 2004
Summary
Implantable cardioverter defibrillator (ICD) therapy effectively prevents sudden cardiac death (SCD) in high-risk patients. While ICDs favorably impact total mortality, their benefit depends on the control group
Area of Science:
- Cardiology
- Medical Devices
- Clinical Trials
Background:
- Sudden cardiac death (SCD) remains a significant concern.
- Implantable cardioverter defibrillators (ICDs) are used for SCD prevention.
- Numerous randomized trials have evaluated ICD therapy.
Purpose of the Study:
- To review randomized trials of ICD therapy versus medical treatment.
- To assess the impact of ICDs on SCD prevention.
- To analyze ICDs' effect on total mortality.
Main Methods:
- Systematic review of randomized controlled trials.
- Comparison of ICD therapy against conventional medical management.
- Analysis of mortality data, including SCD and total mortality.
Main Results:
- ICD therapy is consistently effective in preventing SCD.
- ICDs have generally shown a favorable impact on total mortality.
- The benefit of ICDs on total mortality is influenced by the control group's mortality risk.
Conclusions:
- ICD therapy is a proven strategy for preventing sudden cardiac death.
- Ventricular dysfunction remains a primary predictor of mortality in these patient groups.
- Further research may refine patient selection for ICD implantation.